NASDAQ · CGON
CG Oncology, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for CGON: Nov 13, 2026
CG Oncology, Inc. Common stock is estimated to report earnings on 11/13/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 7 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.86. The reported EPS for the same quarter last year was $-0.57.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.86 | $-0.66 | $-0.96 | 7 |
| Dec 2026 | $-0.90 | $-0.74 | $-1.03 | 6 |
| Mar 2027 | $-0.97 | $-0.87 | $-1.09 | 4 |
| Jun 2027 | $-0.89 | $-0.72 | $-1.05 | 4 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
BNK Invest · Zacks · RTTNews · MarketBeat- BNK Invest · Oct 19, 4:29 PM EDTNotable Monday Option Activity: GE, CGON, BEAmong the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in GE Aerospace (Symbol: GE), where a total of 24,969 contracts have traded so far, representing approximately 2.5 million underlying shares. That amounts to about 62.7% of
- BNK Invest · Sep 22, 3:21 PM EDTNotable Tuesday Option Activity: ASTS, ILPT, CGONAmong the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in AST SpaceMobile Inc (Symbol: ASTS), where a total of 118,093 contracts have traded so far, representing approximately 11.8 million underlying shares. That amounts to abo
- Zacks · Aug 6, 9:50 AM EDTCG Oncology, Inc. (CGON) Reports Q2 Loss, Misses Revenue EstimatesCG Oncology, Inc. (CGON) delivered earnings and revenue surprises of -28.57% and -59.02%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- RTTNews · Jul 27, 6:13 AM EDT5 Stocks That Created Fortunes: CMPS +327%, ARWR +222%, CGON +148%, DRTS +182%, ELMD +86%(RTTNews) – "If you aren't willing to own a stock for 10 years, don't even think about owning it for 10 minutes." – Warren Buffett. The Oracle of Omaha's timeless advice reminds us that patience is one of the key principles of investing.
- BNK Invest · Jul 17, 3:31 PM EDTNotable Friday Option Activity: FIGS, CRWV, CGONLooking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in FIGS Inc (Symbol: FIGS), where a total volume of 24,371 contracts has been traded thus far today, a contract volume which is representative of approximately 2.4
- Zacks · Jul 13, 9:03 AM EDTCG Oncology Stock Gains 12% in Three Months: What's Driving It?CGON climbs as cretostimogene nears a planned 2026 BLA filing, posts encouraging phase II data. It maintains a cash position that supports operations through 2029.
- BNK Invest · Jun 30, 12:01 PM EDTTuesday 6/30 Insider Buying Report: CGON, NXSTBargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned dollars to make a purchase, is that they expect to make money. Today
- MarketBeat · Jun 10, 3:02 AM EDTCG Oncology Eyes Bladder Cancer Breakthrough With Phase 3 Data, Q4 Filing AheadDiscover the 3 Best-Performing Biotech IPO Stocks of 2024CG Oncology (NASDAQ:CGON) Chief Executive Officer Arthur outlined the company’s upcoming clinical and regulatory milestones for cretostimogene during a presentation at the Goldman Sachs Global Healthcare Conference, emphasi
- MarketBeat · Jun 7, 5:05 PM EDTCG Oncology Touts Cretostimogene Data, BLA Progress in Bladder Cancer PushDiscover the 3 Best-Performing Biotech IPO Stocks of 2024CG Oncology (NASDAQ:CGON) is focused on advancing cretostimogene, an oncolytic immunotherapy for non-muscle invasive bladder cancer, Chief Executive Officer Arthur Kuan said during a discussion at the Jefferies Global Healt
- MarketBeat · May 20, 10:04 PM EDTCG Oncology Touts Bladder Cancer Data, Q4 Filing Plans at RBC ConferenceDiscover the 3 Best-Performing Biotech IPO Stocks of 2024CG Oncology (NASDAQ:CGON) executives used an RBC Capital Markets fireside chat to outline recent clinical data for cretostimogene, the company’s investigational therapy for non-muscle invasive bladder cancer, and to discuss
- Fintel · May 19, 1:55 PM EDTWolfe Research Initiates Coverage of CG Oncology (CGON) with Peer Perform RecommendationFintel reports that on May 19, 2026, Wolfe Research initiated coverage of CG Oncology (NasdaqGS:CGON) with a Peer Perform recommendation. Analyst Price Forecast Suggests 44.26% Upside
- MarketBeat · May 15, 3:07 AM EDTCG Oncology BLA Filing on Track as Key Bladder Cancer Data NearsDiscover the 3 Best-Performing Biotech IPO Stocks of 2024CG Oncology (NASDAQ:CGON) executives said the company remains on track to complete a rolling biologics license application for cretostimogene in BCG-unresponsive high-risk non-muscle invasive bladder cancer by the fourth qu
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for CG Oncology, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.